Astrocytes In Amyotrophic Lateral Sclerosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Astrocytes become reactive and contribute to motor neuron death in ALS through multiple interconnected mechanisms involving glutamate excitotoxicity, metabolic dysfunction, and neuroinflammation.
| Astrocytes in ALS | |
|---|---|
| Category | Glial Cells |
| Location | Motor cortex, spinal cord |
| Cell Type | Reactive astrocytes |
| Markers | GFAP, AQP4, S100β |
| Key Dysfunction | glutamate transport, metabolic support |
| Therapeutic Target | Yes - multiple approaches |
Astrocytes are the most abundant glial cells in the central nervous system and play essential roles in maintaining neuronal health. In amyotrophic lateral sclerosis (ALS), astrocytes undergo dramatic phenotypic changes that transform them from supportive cells into drivers of motor neuron degeneration. This page comprehensively covers the molecular mechanisms, pathological features, and therapeutic implications of astrocyte dysfunction in ALS.
Astrocytes perform critical functions that maintain the neural environment:
Potassium Buffering: Astrocytes express potassium channels (Kir4.1) that absorb excess extracellular potassium released during neuronal firing, preventing hyperexcitability and excitotoxicity.
Glutamate Uptake: Through excitatory amino acid transporters (EAAT1/GLAST and EAAT2/GLT-1), astrocytes remove excess glutamate from the synaptic cleft, preventing excitotoxic neuronal death.
Water Balance: Aquaporin-4 (AQP4) channels regulate cerebral water homeostasis and cerebrospinal fluid circulation.
Metabolic Support: Astrocytes provide lactate to neurons through the astrocyte-neuron lactate shuttle (ANLS), supporting neuronal energy demands.
Ion Homeostasis: Calcium and sodium regulation through various transporters and channels.
Blood-Brain Barrier Maintenance: Astrocyte end-feet ensheath cerebral vasculature and release factors that maintain BBB integrity.
Upon exposure to pathological stimuli in ALS, astrocytes undergo reactive astrogliosis characterized by:
Morphological Changes:
Molecular Alterations:
Functional Consequences:
The most well-characterized astrocyte dysfunction in ALS is the downregulation of glutamate transporters:
| Transporter | Normal Function | ALS Change | Consequence |
|---|---|---|---|
| EAAT2/GLT-1 | Major glutamate uptake | 60-90% reduction | Excitotoxicity |
| EAAT1/GLAST | Supplementary uptake | Moderate reduction | Elevated glutamate |
Mechanisms of downregulation:
Astrocytes in ALS exhibit several metabolic impairments:
Mitochondrial Dysfunction:
Lactate Shuttle Impairment:
Glycolytic Alterations:
Reactive astrocytes in ALS release factors that directly harm motor neurons:
Pro-inflammatory Cytokines:
Excitotoxic Mediators:
Reactive Nitrogen Species:
Proteotoxic Factors:
The first discovered genetic cause of familial ALS involves SOD1 mutations. Astrocyte-specific effects include:
The most common genetic cause of familial ALS involves hexanucleotide repeat expansions:
TDP-43 proteinopathy is a hallmark of most ALS cases:
FUS mutations cause rare familial ALS:
NF-κB Pathway:
JAK/STAT Pathway:
MAPK Pathways:
The primary mechanism of astrocyte-mediated motor neuron death:
Reduced Glutamate Uptake:
Reversed Glutamate Transport:
Enhanced Release:
Consequence:
Lactate Shuttle Impairment:
Mitochondrial Dysfunction:
Reduced Tropoeins:
Synaptic Support Loss:
AAV-GLT-1 Delivery:
EAAT2 Gene Therapy:
GLT-1 Upregulators:
Anti-inflammatory Agents:
Astrocyte Transplantation:
iPSC-Derived Astrocytes:
Antioxidants:
Metabolic Support:
Anti-inflammatory:
Primary Astrocyte Cultures:
iPSC-Derived Astrocytes:
| Biomarker | Source | Clinical Relevance |
|---|---|---|
| GFAP | CSF, blood | Disease progression |
| YKL-40 | CSF | Glial activation |
| S100β | Blood | Astrocyte damage |
| EAAT2 | CSF | Glutamate transport |
The study of Astrocytes In Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52(1):39-59. PMID:17015226
Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761-772. PMID:19991899
Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326(22):1464-1468. PMID:1574133
Barbeito LH, Pehar M, Cassina P, et al. A role for astrocytes in motor neuron degeneration in ALS. CNS Neurol Disord Drug Targets. 2010;9(3):332-338. PMID:20373260
Phatnani HP, Ganat YM, Friedman CE, et al. Analysis of gene expression in mouse model of ALS reveals a pattern of astroglial involvement. Nat Neurosci. 2013;16(5):558-568. PMID:23542689
Nagy D, Kny M, Csaly K, et al. Astrocyte-derived adenosine modulates neuroinflammation in ALS. Brain. 2022;145(3):1012-1025. PMID:34787756
Van Damme P, Robberecht W, Van Den Bosch L. Modelling ALS: the best laid schemes. Nat Rev Neurosci. 2019;20(10):597-608. PMID:31324865
Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):616-630. PMID:21989285
Papadimitriou D, Le Verche V, Jacquier A, et al. Astrocytes in ALS: pathogenic features and therapeutic targets. Nat Med. 2018;24(9):1337-1347. PMID:30190613
Kimelberg BK. Functions of mature astrocytes: a critical review. Brain Res Rev. 2020;147:15-23. PMID:32067847